Antisense Oligonucleotides Restore TDP-43 RNA Binding Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for TDP-43 pathologies, such as ALS and FTLD, fail to effectively restore RNA binding protein functionality, leading to persistent dysregulation of RNA processing and splicing abnormalities.
Innovation Solution
Development of antisense oligonucleotides complementary to TDP-43 binding sites on RNA transcripts, which restore the functional phenotype of TDP-43 target RNAs by modulating splicing and expression in TDP-43 depleted cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for TDP-43 pathologies, then TDP-43 pathologies are treated, but RNA binding protein functionality is not restored and splicing abnormalities persist
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to TDP-43 RNA binding sites on target RNAs, thereby restoring proper splicing and RNA processing without directly replacing the depleted TDP-43 protein. The oligonucleotides act as mediators between the depleted TDP-43 system and the target RNAs, correcting splicing abnormalities in a indirect manner.
Solution Approach 2:
The antisense oligonucleotides are designed to be complementary copies of the TDP-43 binding sites on target RNAs. By creating these complementary copies, the oligonucleotides can bind to the same RNA sequences that TDP-43 normally binds, thereby replicating TDP-43's functional role in RNA processing and splicing regulation.
2Manufacturing precision
If antisense oligonucleotides complementary to TDP-43 binding sites are used, then RNA processing fidelity is enhanced, but device complexity increases
Solution Approach 1:
The patent employs parameter changes by modifying the oligonucleotide sequence parameters to match specific TDP-43 binding site characteristics. By adjusting parameters such as sequence complementarity, length, and binding affinity, the oligonucleotides achieve high fidelity in restoring RNA processing while maintaining a relatively simple therapeutic approach.
3Adaptability or versatility
If TDP-43 binding sites on multiple RNA transcripts are targeted, then functionality is restored across multiple targets, but specificity requirements increase
Solution Approach 1:
The patent applies universality by designing antisense oligonucleotides that can bind to conserved TDP-43 binding site motifs present across multiple different RNA transcripts. The oligonucleotides are engineered with sequence characteristics that allow them to recognize and bind to the common UG-rich or GU-repeat motifs found in TDP-43 binding sites on various target RNAs, enabling multi-target restoration of function.
Solution Approach 2:
The patent uses local quality by focusing the oligonucleotide binding specificity on the local sequence characteristics of TDP-43 binding sites (such as UG-repeats and GU-motifs) rather than requiring perfect complementarity across the entire RNA transcript. This allows the oligonucleotides to bind specifically to TDP-43 binding sites while tolerating sequence variations in different target RNAs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense oligonucleotides effectively enhance the fidelity of RNA processing events, correcting aberrant splicing and restoring normal gene expression in cells with reduced TDP-43 levels, thereby offering a novel therapeutic approach for TDP-43 pathologies.
Implementation Method 1
antisense oligonucleotides which are complementary, such as fully complementary, to RNA binding protein target sites on multiple RNAs
Data Source
AI summary
The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells.